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Abstract 
Background: Although the population-based German disease management programs (DMPs) for diabetes mellitus 
(DM) and coronary heart disease (CHD) are among the biggest worldwide, evidence on the effectiveness of these 
programs is still inconclusive or missing, particularly for high risk patients with comorbidities. The objective of this 
study was therefore to analyze the impact of DMPs on process and outcome parameters in patients with both, type 2 
DM and CHD.
Methods: Analyses are based on two postal surveys of patients from the KORA myocardial infarction registry (south-
ern Germany) with type 2 DM and on two postal validation studies with patients’ general physicians (2006, n = 312 
and 2011, n = 212). The association between DMP enrollment (being enrolled in either DMP-DM or DMP-CHD) and 
guideline care (defined by several process indicators) at baseline (2006) and its development until follow-up (2011) 
was analyzed using logistic regression models accounting for the repeated measurements structure. The impact of 
DMP enrollment/guideline care on cumulated (quality-adjusted) life years ((QA)LYs) over a 4-year time horizon (2006–
2010) was assessed using multiple linear regression methods. Logistic regression models were applied to analyze the 
association between DMP status and patient self-management at follow-up.
Results: Being enrolled in a DMP was associated with better guideline care at baseline [OR = 2.3 (95 % CI 1.27–4.03)], 
but not at follow-up [OR = 0.80 (95 % CI 0.40–1.58); p value for time-interaction <0.01]. DMP enrollment was not 
significantly [+0.15 LYs (95 % CI –0.07, 0.37); +0.06 QALYs (95 % CI –0.15, 0.26)], but treatment according to guideline 
care significantly [+0.40 LYs (95 % CI 0.21–0.60); +0.28 QALYs (95 % CI 0.10–0.45)] associated with higher (quality-
adjusted) survival over the 4-year follow-up period. DMP enrollees further reported a somewhat better self-manage-
ment than patients not being enrolled into a DMP.
Conclusions: The results of this study concerning the effectiveness of DMPs in patients with DM and CHD are mixed, 
but are weakly in favor of DMPs. However, we found a clear positive impact of guideline care on quality adjusted sur-
vival in this patient group. The development of the association between DMP enrollment and guideline care over the 
follow-up time indicates some external effects, which should be the subject of further investigations.
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Background
Metabolic and cardiovascular diseases (CVD) are inter-
related public health problems causing substantial eco-
nomic pressure on health care systems [1, 2]. As the 
prevalence of diabetes mellitus (DM) is currently rising in 
Germany and in most other countries and as diabetes is a 
major risk factor for CVD, the burden of these diseases is 
expected to increase further [3–5]. Specifically, high risk 
individuals with co-existing cardiovascular and metabolic 
diseases need intensive treatment to prevent macro-vas-
cular complications. Owing to their similar pathogenesis 
[6], treatment guidelines in both diabetes and coronary 
heart disease (CHD) focus on the management of CVD 
risk factors through modification of lifestyle habits and 
medication therapy as these strategies have been shown 
to improve patient outcomes [7–13]. In order to reinforce 
guideline care and to improve quality of care for chroni-
cally ill patients, in the years 2002/2003, disease manage-
ment programs (DMPs) for DM and CHD were rolled out 
nationwide in Germany within the statutory health insur-
ance (SHI) system, a system of non-profit health insur-
ance companies insuring ~88 % of the population [14]. In 
comparison to disease management programs in other 
countries which often focus on high risk patients and are 
heterogeneous in their structure, German DMPs are pop-
ulation-based approaches and characterized by a high 
degree of homogeneity. In Germany, the “Federal Joint 
Committee” (Gemeinsamer Bundesausschuss) which is 
responsible for decision-making and quality assurance 
in the inpatient and outpatient health care sector passes 
directives and content requirements for structured DMPs 
[15]. All DMPs must obtain approval from the German 
“Federal Insurance Agency” (Bundesversicherungsamt), 
which controls the quality standards passed by the Fed-
eral Joint Committee [14, 16]. Within these programs, 
general practitioners (GPs) act as gatekeepers respon-
sible for (voluntary) enrollment of eligible patients and 
coordination of care. The key contents of the DMP-DM 
and DMP-CHD are enforcement of medication therapy, 
enhanced patient activation and patient self-management 
education (e.g., diet, physical activity, smoking cessa-
tion), continuity of care according to current guidelines 
and the use of information technology systems for rou-
tine documentation/benchmarking [16]. Details includ-
ing the roles of GPs, patients and health insurances as 
well as reimbursement schemes have been described 
elsewhere [17, 18]. Although around 4.0 million patients 
with type 2 DM and 1.8 million patients with CHD are 
enrolled in the respective German DMPs, a scientifically 
sound evaluation of the programs has appeared to be 
difficult [16]. Important clinical information is only rou-
tinely collected for DMP participants, but not for non-
DMP patients, and running randomized trials is hardly 
possible, as by law patients have the right to be enrolled 
into the appropriate programs [19, 20]. Therefore, the 
evidence on the effectiveness of DMPs mainly relies on 
non-randomized group comparisons based on a limited 
subset of information from routine claims [17, 18, 21, 22] 
or population-based survey data [23–28]. These studies 
show mixed results on survival and better quality of care 
for patients enrolled in the respective DMPs. However, 
due to the population-based focus of German DMPs, no 
study has examined the effectiveness of DMPs in terms 
of process and outcome quality in multi-morbid high risk 
patients. In addition, although patient education is one of 
the key DMP contents [16, 29, 30], very little is known 
about the impact of these education programs on patient 
self-management.
This study aims to evaluate the effectiveness of German 
DMPs in patients with coexistence of diabetes and CHD 
using longitudinal follow-up data from a registry-based 
population (myocardial infraction registry). In detail, we 
analyzed the impact of DMP enrollment (either DMP-
DM or DMP-CHD) on guideline care, the impact of DMP 
enrollment/guideline care on 4-year (quality-adjusted) 
survival, and on patient self-management.
Methods
Data source
Data for this study originated from the core documenta-
tion of the KORA (Cooperative Health Research in the 
Region of Augsburg) myocardial infarction (MI) regis-
try and two postal questionnaire waves (2006 and 2011) 
in MI registry patients and their respective GPs. The 
KORA MI registry collects information on all cases of 
coronary deaths and non-fatal MIs of inhabitants aged 
25–74 years in the city of Augsburg and two surrounding 
counties [31]. Of the 2950 participants who were alive in 
2006 (n = 4394, response ~67 %) and answered an initial 
postal survey (patient survey 1) assessing basic informa-
tion on socioeconomic status, lifestyle habits, risk fac-
tors, medication, and quality of life (QoL), 2563 were 
insured in the SHI system at the date of MI. As DMP 
names vary considerably between statutory health insur-
ance companies and may not reveal the disease manage-
ment aspect, the information about the DMP status was 
assessed from the patients’ GPs. For this, all GPs of stat-
utorily insured participants who reported DMP-CHD 
Keywords: Diabetes, Coronary heart disease, Disease management programs, Guideline care, (Quality-adjusted) 
survival, Self-management
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enrollment (n = 665) and a subsample of the GPs of stat-
utorily insured patients who denied DMP-CHD enroll-
ment (n  =  583) were asked to provide information on 
the DMP status of their patients (validation survey 1). 
The GPs of 1128 patients answered this questionnaire. 
For several reasons, 153 patients were excluded from 
further study (details in Fig.  1). Of the remaining 975 
patients, 312 were identified as having type 2 diabetes. 
Information on the diabetes status and the type of dia-
betes was extracted from the GP questionnaires. If the 
physicians’ information on diabetes status was missing, 
the information provided by the patient was used (sen-
sitivity 80  %; specificity 99  %). Up to the end of 2010, 
141 patients died (62 of those with type 2 diabetes) and 
681 of the patients still alive answered a second postal 
questionnaire in 2011 (patient survey 2), assessing the 
same variables as in 2006, plus information on patient 
self-management behavior. As in 2006, GPs were con-
tacted again in 2011, and information on diabetes and 
DMP status was retrieved for 524 patients through a 
postal questionnaire (validation survey 2). Of those 524 
patients, 210 were identified as having type 2 diabetes; 
144 already had a diagnosis in 2006 and 66 were incident 
cases between 2006 and 2011. Only patients with physi-
cian-validated information on DMP status (n =  312 in 
2006 and n = 210 in 2011) were included in the analy-
sis, as previous analyses have shown that the validity 
of patient self-reports on their DMP status is low [32]. 
The detailed study design and patient selection are illus-
trated in Fig.  1. Data collection and analyses related to 
the registry have been approved by the Bavarian Ethics 
Committee.
n= 62 died 
n= 54 lost 
KORA MI-Registry: 
• All paents with an acute MI between 1985 and 2004 
and being alive in 2006 
n=4394   
(n=3867 with SHI at date of MI) 
1st paent Quesonnaire (2006) 
• Basic informaon on socioeconomic status, life style 
habits, risk factors, medical history, medicaon and 
QoL
n=2950 
(n=2563 with  SHI at date of MI ) 
1st GP Quesonnaire (2006/2007) 
• Basic informaon on diabetes status and  DMP status  
n=1128 
Further exclusion (n=153) * 
n=975 (remaining sample) 
Validaon of diabetes and DMP status 
• On all paents reporng DMP 
enrollment; n=665 
• On ~ 1/3 of all paents  with SHI 
not reporng enrollment; n=583 
2nd paent Quesonnaire (2011) 
• Basic informaon on socioeconomic status, life style 
habits, risk factors, medical history, medicaon and QoL 
• Detailed informaon on quality of diabetes and CHD care, 
self-management and health care ulizaon
n=681 
2nd GP Quesonnaire (2011) 
• Basic informaon on diabetes status  and  DMP status 
n=524 
Study design and paent selecon 
Validaon of  diabetes and DMP status
• On all paents answering the 2nd
quesonnaire 
• N=312 with type 2 diabetes 
• N=663 without  type 2 diabetes 
• N=210  with type 2 diabetes ** Incident cases:  
n=66 
Prevalent cases:  
n=144 
n= 79 died 
n= 99 lost 
Fig. 1 Study design and patient selection. *DMP status not reported by physician (n = 29), patient not cared for by physician (n = 31), patient is 
privately insured (n = 79), patient not eligible for DMP (n = 8), patient questionnaire empty (n = 6). **3 inconsistent cases (diabetes type 2 indica-
tion in 2006, but not in 2011) were excluded
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Measures
DMP enrollment
Information about the patients’ DMP enrollment status 
was extracted from the GP questionnaire in 2006 and 
2011. All patients in the analyzed sample were eligible for 
enrollment in both DMP-CHD and DMP-DM. Therefore, 
a patient was classified as being a DMP enrollee if enroll-
ment in one or in both of these programs was reported.
Guideline care
Treatment of patients in the DMP-CHD and DMP-DM 
should be based on national treatment guidelines [16], 
which include among other criteria, counseling for the 
topics physical activity, diet, and smoking cessation and 
treatment with statins, platelet aggregation inhibitors 
(PAI), and antihypertensive drugs [either renin–angio-
tensin inhibitors (RAI) or beta blocker] [33, 34]. As in a 
previous study, we defined guideline care as being present 
if: (a) a patient had received medical advice over the last 
12 months on at least two out of the three lifestyle topics 
(smoking, diet, exercise) and (b) reported the intake of a 
PAI and a statin and either RAI or a beta blocker over the 
last 7 days [27].
Quality of life, survival, and quality‑adjusted survival
Information on the vitality status of patients was obtained 
by address search and by contacting the regional regis-
tration authorities. Survival times started at the fill-in 
date of the patient’s questionnaire in 2006 and ended at 
date of censoring or death. Quality of life was assessed 
in both patient questionnaires (2006 and 2011) using 
the EQ-5D instrument and utility values were calculated 
using a scoring algorithm derived from the general Ger-
man population [35]. Combining survival times and QoL, 
accumulated (quality-adjusted) life years ((QA)LYs), a 
measure that accounts for both the length and the qual-
ity of life over a certain observation period, were assessed 
individually for each person according to the methodol-
ogy described by Laxy et al. [36].
Self‑management
Patient self-management was defined by means of pre-
vious established criteria [26, 37–40]. The binary indi-
cators, comprised of regular moderate physical activity 
(≥5 h per week) [40] and regular (at least once a week) 
self-monitoring of blood glucose (SMBG), blood pres-
sure (SMBP), and body weight (SMBW), were extracted 
from the patients’ self-reports [26, 37, 38]. Medication 
adherence was assessed according to the German version 
of the Morisky Medication Adherence Scale (MMAS-4 
score <1) [39]. As an indicator of patient knowledge, it 
was asked if patients knew about the term “HbA1c” as 
a performance measure for long-term glucose control. 
Furthermore, it was assessed whether patients partici-
pated in an education class for diabetes or blood pressure 
control.
Statistical analysis
Descriptive statistics of the samples’ characteristics in 
2006 (n  =  312) and 2011 (n  =  210) and p-values (Chi 
square tests for categorical variables and t-tests for con-
tinuous variables) for the differences between DMP 
enrollees and non-enrollees and between patients receiv-
ing guideline vs. those not receiving guideline care are 
reported.
In order to test whether DMP enrollment is a pre-
dictor for receiving guideline care and to test how this 
association developed over time, we used a general-
ized estimating equation (GEE) model with a logit-link, 
which accounts for the partly repeated measurement 
structure of the sample and included an interaction 
term between DMP status (yes vs. no) and time (2006 
vs. 2011). Linear regression and Cox proportional haz-
ard regression was applied to test the impact of the 
DMP status/guideline care on QoL changes and mor-
tality over the 4-year follow-up period (2006–2010). 
Differences in accumulated (quality-adjusted) life years 
over the follow-up period for DMP status/guideline 
care were tested through linear regression in order 
to obtain an absolute measure for the achieved health 
gains. Finally, we applied logistic regression to assess 
the cross-sectional association between DMP/guideline 
care and the patients’ self-management in 2011. A more 
sophisticated analysis of the association with self-man-
agement was not possible, as self-management was only 
assessed in the 2011 survey.
As part of our additional exploratory analyses, we fur-
ther examined separately the impact of DMP-DM and 
DMP-CHD to capture potential differences in the effec-
tiveness of these programs.
All models were adjusted for the covariates age (con-
tinuous), sex, educational status (primary education: 
≤9  years of school; secondary and tertiary education: 
>9  years of school), smoking status (never smoker, ex-
smoker, current smoker), weight status (normal weight: 
Body Mass Index (BMI) < 25; overweight: 25 ≤ BMI < 30; 
obese: BMI  ≥  30), number of re-infarctions in 2006 
(continuous), treatment status (no medication, oral anti-
diabetic medication only, insulin therapy with or with-
out oral antidiabetic medication) and diabetes duration 
(<5  years, 5≤ years  <10 years, ≥10  years), which were 
extracted from self-reports of the surveys in 2006 and 
2011 and from the core database of the MI registry. Lin-
ear regression models analyzing the difference in accu-
mulated QALYs were also adjusted for QoL at baseline 
(2006). For each association, a separate regression model 
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was built up including only the predictor of interest and 
the specified set of covariates.
Results
Characteristics of the study population
The characteristics of the 2006 and 2011 sample are 
shown in Table  1. The mean age of the sample was 
68.2  years in 2006 and 72.1  years in 2011. Mean diabe-
tes duration (mean duration since the first registry-regis-
tered MI) averaged ~9 (~9) years in 2006 and ~10 (~14) 
years in 2011. As patients originate from a MI registry, 
almost 80  % of people were male. In 2011, 77  % (2006, 
76 %) were enrolled in one of the two DMPs, and 61 % 
(2006, 62  %) were treated according to guideline care. 
DMP enrollees and non-enrollees were quite comparable 
but patients receiving guideline care were on average sig-
nificantly younger and reported higher QoL values than 
those not receiving guideline care.
Association between DMP status and guideline care
Table  2 depicts the association between DMP status 
and guideline care and how this relationship changed 
from 2006 to 2011. In 2006, patients enrolled in one of 
the two DMPs were 2.3 times (95 % CI 1.27–4.03) more 
likely to receive guideline care than patients not enrolled 
in a DMP. However, although the portion of DMP enroll-
ees receiving guideline care remained relatively stable 
until 2011, the portion of non-DMP enrollees increased 
substantially, resulting in a non-significant association 
between DMP enrollment and guideline care (OR = 0.80, 
95  % CI 0.40–1.58). The interaction term for this effect 
was highly significant (p = 0.009). A similar pattern was 
observed for enrollment in DMP-CHD or DMP-DM 
only.
Association between DMP status/guideline care 
and (quality‑adjusted) survival
Table  3 shows the relationship between DMP status/
guideline care and QoL changes and mortality respec-
tively. Effect estimates from the linear regression model 
show that neither DMP enrollment nor guideline care 
was significantly associated with QoL change over 
the follow-up period. The results from the Cox pro-
portional hazard regression show that enrollment in a 
DMP was not significantly associated with mortality 
(HR  =  0.80; 95  % CI 0.45–1.41). Separate analyses for 
DMP-CHD (HR =  0.74; 95  % CI 0.44–1.25) and DMP-
DM (HR =  0.91; 95  % CI 0.54–1.54) also showed non-
significant associations.
Treatment according to guideline care was also not 
associated with QoL change, but was a very strong pre-
dictor of mortality (HR = 0.27; 95 % CI 0.15–0.47). More 
detailed analyses on the single dimensions of guideline 
care are illustrated in Additional file  1: Appendix 1. All 
dimensions were associated with a significant or non-sig-
nificant mortality risk reduction (advice diet, HR = 0.57, 
p  =  0.12; advice exercise, HR  =  0.65, p  =  0.15; beta-
blockers, HR  =  0.27, p  <  0.001; statins, HR  =  0.40, 
p < 0.01; PAI, HR = 0.47, p = 0.05; RAI = 0.69, p = 0.10).
Table 4 shows the relationship between DMP status/
guideline care and (quality-adjusted) survival. Enroll-
ment in a DMP was not significantly associated with 
accumulated LYs (+0.15, 95  % CI −0.07 to 0.37) and 
QALYs (+0.06; 95  % CI −0.15 to 0.26). Additional 
analyses showed that DMP-CHD was (borderline) sig-
nificantly associated with accumulated LYs (β =  0.21, 
95  % CI 0.02–0.40) and QALYs (β  =  0.16, 95  % CI 
0.00–0.33). The discrepancy between the non-sig-
nificant HR and the (borderline) significant absolute 
effect estimates (LYs, QALYs) for DMP-CHD status 
results mainly from a shorter survival time of people 
who die, which is not accounted for by the non-para-
metric Cox model.
Guideline care was strongly associated with longer sur-
vival (+0.40 LYs, 95 % CI 0.21–0.60) and quality-adjusted 
survival (+0.28 QALYs, 95  % CI 0.10–0.45) over a time 
frame of ~4  years. Detailed analyses showed, that par-
ticularly patients taking beta-blockers (+0.29 QALYs, 
95 % CI 0.06–0.52), statins (+0.25 QALYs, 95 % CI 0.04–
0.46), and PAI (+0.25 QALYs, 95 % CI 0.04–0.46) had a 
substantially higher quality-adjusted survival over the 
follow-up period.
Association between DMP status/guideline care 
and self‑management
Figure 2 shows the association between DMP/treatment 
status and important dimensions of self-management. 
Overall, patients enrolled in a DMP reported better self-
management (almost all OR >1); however, only patient 
knowledge (“knowing the term HbA1c”) (OR: 3.05, 95 % 
CI 1.13–8.20) was significantly associated with DMP 
enrollment. Separate analyses for DMP-DM and DMP-
CHD showed a similar pattern. Overall, the uncertainty 
around effect estimates was large.
Discussion
This is the first study in Germany and one of the first 
studies internationally evaluating the effect of structured 
DMPs in individuals with both DM and CHD, a patient 
group known to have a high risk of fatal and non-fatal 
cardiovascular events [29, 41]. In addition, to our knowl-
edge it is the only study in Germany on DMPs which uses 
data after 2007 [26, 29]. Overall, we found mixed results 
for the association between DMP enrollment and patient 
outcomes in high risk patients, which are weakly in favor 
of DMPs. DMP enrollment was positively associated with 
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guideline care at the beginning of the study (2006), but not 
any longer the end of the study (2011). Although guideline 
care at baseline (2006) was identified as a strong predictor 
for (quality-adjusted) survival, we found no evidence for 
an impact of DMP enrollment on (quality-adjusted) sur-
vival over a time period of 4 years. In contrast, DMPs were 
weakly associated with better patient self-management.
At baseline (2006) the likelihood of receiving guideline 
care was more than doubled for those patients enrolled in 
a DMP for CHD and/or DM. This is congruent with previ-
ous studies, which clearly have shown that DMPs are asso-
ciated with improvements in process parameters such as 
medical examinations, lifestyle counseling, and medication 
for secondary prevention of CHD [26–28, 42]. Interest-
ingly, although the prevalence of receiving guideline care 
in the group of DMP enrollees stayed constant or went 
down slightly, the prevalence of receiving guideline care 
in the non-DMP group in this study went up substantially 
from 2006 to 2011. This significant interaction between the 
effects of DMP and time could be an indicator of a spill-
over effect. It is possible that, with the implementation of 
DMPs and corresponding physician education require-
ments, physicians started to apply the adopted standards 
to all treated patients. However, alternative explanations 
such as altered patterns of enrollment regarding patient 
characteristics (education, socioeconomic status) or other 
external effects might be possible, as well.
The results of our study further show that general DMP 
enrollment in high risk patients was weakly, but non-signif-
icantly associated with (quality-adjusted) survival. Previous 
studies based on claims data from the BARMER (n ~40,000, 
mortality: RR = 0.48) and the AOK (n ~4000, HR = 0.68) 
health insurances companies reported significant mortality 
risk reductions for general diabetes patients enrolled in a 
DMP-DM [18, 24]. However, our non-significant results are 
Table 2 Adjusted odds ratios (OR) on the association between DMP status and guideline care in 2006 and 2011 with an 
interaction term DMP status x time
Models adjusted for age, sex, education, smoking status, weight status, treatment status, number of reinfarctions, and diabetes duration
DMP disease management program, CHD coronary heart disease, DM diabetes mellitus
a Counseling on two out of the three lifestyle topics (smoking, diet, exercise) and intake of a platelet aggregation inhibitor and a statin and either renin–angiotensin 
inhibitors or a beta blocker
 Treatment 
status 
General estimating equation model with logit link DMP status x time
p‑value
Guideline care in 2006a Guideline care in 2011a
% OR (95 % CI) % OR (95 % CI)
DMP (CHD or DM)
 No 45.7 Ref. 62.2 Ref.
 Yes 67.0 2.27 (1.27–4.03) 60.9 0.80 (0.40–1.58) 0.009
DMP-CHD (only)
 No 54.7 Ref. 62.1 Ref.
 Yes 69.3 1.91 (1.17–3.14) 60.8 0.92 (0.50–1.70) 0.035
DMP-DM (only)
 No 55.4 Ref. 59.0 Ref.
 Yes 66.0 1.48 (0.88–2.46) 62.7 0.96 (0.52–1.76) 0.231
Table 3 Adjusted hazard rations (HR) and  adjusted mean 
differences on the association between DMP status/guide-
line care and mortality/QoL change
Models adjusted for age, sex, education, smoking status, weight status, 
treatment status, number of reinfarctions, and diabetes duration
DMP disease management program, CHD coronary heart disease, DM diabetes 
mellitus, QoL quality of life
a Counseling on two out of the three lifestyle topics (smoking, diet, exercise) 
and intake of a platelet aggregation inhibitor and a statin and either renin–






Mortality Change in EQ‑5D 
per year
HR (95 % CI) Beta (95 % CI)
DMP (CHD or DM)
 No Ref. Ref.
 Yes 0.80 (0.45 to 1.41) −0.009 (−0.029 to 0.011)
Guideline carea
 No Ref. Ref.
 Yes 0.27 (0.15 to 0.47) −0.003 (−0.021 to 0.014)
DMP-CHD (only)
 No Ref. Ref.
 Yes 0.74 (0.44 to 1.25) 0.003 (−0.013 to 0.019)
DMP-DM (only)
 No Ref. Ref.
 Yes 0.91 (0.54 to 1.54) 0.002 (−0.014 to 0.019)
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in line with a study by Stark et al. on all participating CHD 
patients (with and without diabetes) from the same registry-
based data source, which showed a moderate but non-sig-
nificant mortality risk reduction (n = 975, HR = 0.90) for 
patients being enrolled in a DMP-CHD [27]. In Stark et al.’s 
study, guideline care was found to be a strong predictor of 
mortality in CHD patients (HR =  0.40). Our study shows 
that this association is even stronger in high risk CHD 
patients with metabolic comorbidity (HR  =  0.28), result-
ing in a 0.28 QALYs longer quality-adjusted survival over 
Table 4 Adjusted mean differences on  the association between  DMP status/guideline care and  accumulated LYs/QALYs 
over the 4-year follow-up period
DMP disease management program, CHD coronary heart disease, DM diabetes mellitus, LYs (unadjusted) life years, QALYs quality adjusted life years
a Models adjusted for age, sex, education, smoking status, weight status, treatment status, number of reinfarctions, and diabetes duration
b Models adjusted for (a) and QoL at baseline
c Counseling on two out of the three lifestyle topics (smoking, diet, exercise) and intake of a platelet aggregation inhibitor and a statin and either renin–angiotensin 
inhibitors or a beta blocker
Treatment status in 2006 Linear regression model Linear regression model
Difference in accumulated LYsa Difference in accumulated QALYsb
Adj. mean Beta (95 % CI) Adj. mean Beta (95 % CI)
DMP (CHD or DM)
 No 3.64 Ref. 2.95 Ref.
 Yes 3.78 0.15 (−0.07 to 0.37) 3.01 0.06 (−0.15 to 0.26)
Guideline carec
 No 3.51 Ref. 2.83 Ref.
 Yes 3.91 0.40 (0.21 to 0.60) 3.11 0.28 (0.10 to 0.45)
DMP-CHD (only)
 No 3.65 Ref. 2.92 Ref.
 Yes 3.86 0.21 (0.02 to 0.40) 3.08 0.16 (0.00 to 0.33)
DMP-DM (only)
 No 3.70 Ref. 2.98 Ref.
 Yes 3.78 0.08 (−0.11 to 0.28) 3.00 0.02 (−0.16 to 0.20)
Adjusted Odds Raos (OR) on the associaon between DMP-status/guideline care and dimensions of self-management
Logisc regression model
0.1 1 10




adherent to medicaon (83%)
knowing "HbA1c" (72%)
BP educaon class (15%)
DM educaon class (74%)
0.1 1 10
DMP (CHD or DM)
(yes vs. no)
OR (95% - CI)
Guideline care
(yes vs. no)
OR (95% - CI)
Self-management
(proporon in sample reporng "yes")
0.1 1 10 0.1 1 10
DMP-CHD (only)
(yes vs. no)
OR (95% - CI)
DMP-DM (only)
(yes vs. no)
OR (95% - CI)
Fig. 2 Adjusted odds ratios (OR) on the association between DMP-status/guideline care and dimensions of self-management. DMP disease man-
agement program, CHD coronary heart disease, DM diabetes mellitus, PA physical activity, SM self‐monitoring, BG blood glucose, BP blood pressure, 
BW body weight, HbA1c glycated hemoglobin; Guideline care counselling on 2 out of the 3 lifestyle topics (smoking, diet, exercise) and intake of 
a platelet aggregation inhibitor and a statin and either a renin angiotensin inhibitors or a beta blocker; models adjusted for age, sex, education, 
smoking status, weight‐status, treatment status, number of re‐infarctions and diabetes duration; exact point estimates and 95 % CI are reported in 
Additional file 2: Appendix 2
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a 4-year time frame. The main driver for this strong effect 
in our study was medication with beta-blockers, statins, 
and PAI indicating that secondary prevention accord-
ing to current German national guidelines might prolong 
life expectancy at a high level of QoL and should therefore 
have a high priority in the disease management process. 
Beyond medication and regular check-ups, involvement 
and education of patients aiming to enhance self-manage-
ment behavior are core contents of the DMPs [16, 17]. This 
study shows that at follow-up patients with diabetes and 
CHD who were enrolled in a DMP reported slightly better 
self-management; however, owing to a high magnitude of 
uncertainty, most of these associations were not significant. 
These findings contribute to the very limited literature on 
this topic. The only German study that analyzed the asso-
ciation between DMP enrollment and self-management 
was based on diabetes patients only and reported that DMP 
enrollees were more likely to have participated in a diabetes 
education class, however, behavioral aspects such as self-
monitoring of feet, blood glucose, or weight were also not 
significantly improved [26]. As previous research indicated 
that self-management is a crucial factor for intermediate 
and long-term health outcomes, future studies evaluating 
the effectiveness of DMPs should incorporate dimensions of 
self-management as separate outcome measures to improve 
the evidence on this important topic [38, 43].
Our exploratory analyses indicated that both programs, 
DMP-DM and DMP-CHD, were associated with slightly 
better outcomes in this high risk population. Although 
some effects were slightly stronger for DMP-CHD, there 
is not enough evidence to assume that these differences 
occurred systematically.
The strong association between guideline care and 
(quality-adjusted) survival and the diminishing associa-
tion between DMP enrollment and guideline care over the 
follow-up time are of great (political) relevance when it 
comes to the discussion about the meaningfulness of Ger-
man DMPs: given the assumption that positive effects of 
DMPs are translated through delivery of guideline care, it is 
likely that the positive impact of DMPs on survival that had 
been reported in studies on data before 2007 will have been 
attenuated in recent years. Contrarily, one can argue that in 
case of a potential treatment spill-over the implementation 
of DMPs was an effective strategy for improving health care 
and health outcomes on the population level. Due to its 
moderate sample size and potentially limited generalizabil-
ity this study might not provide enough evidence to derive 
externally valid conclusions on this question, however, the 
results of this study can be seen as an important guidepost 
for future research. To answer the question about the over-
all effectiveness of German DMPs in normal and high-risk 
patients, larger studies with up to date data are needed. 
Linking registry-based or population-based survey data, 
comprising detailed information on behavioral and clini-
cal parameters, with administrative claims data, compris-
ing detailed information about delivered care, seems to be a 
promising approach in this context [44].
The strength of this study is its registry-based longi-
tudinal design and the analysis of different disease man-
agement dimensions. The use of patient self-reports and 
physician-validated information on DMP status at baseline 
and follow-up made it possible to comprehensively ana-
lyze the association between DMP status, guideline care, 
mortality, and self-management over the follow-up period. 
In addition, parallel to classical Cox proportional hazard 
regression, we applied a method that allows the quantifi-
cation of quality-adjusted survival based on individual-
level longitudinal survey data [36]. This approach has two 
advantages. First, it not only accounts for the length of life, 
but also for the health state people live in. This is particu-
larly of interest in older multi-morbid populations where 
health gains (longer survival) are often achieved through 
intensive treatment regimens, which in turn might nega-
tively affect QoL. Second, absolute measures for health 
gains are generally needed for the assessment of the cost-
effectiveness of interventions. Taking the means and 
standard errors of published effects (QALYs) and a certain 
societal willingness to pay threshold allows one to roughly 
estimate up to which costs DMPs and guideline care would 
be considered to be cost-effective.
The major limitation of this study is its non-rand-
omized observational design. Therefore, selection bias 
and, consequently, effects of reverse causation cannot be 
ruled out. One big source of selection bias might be the 
inclusion criteria of German DMPs themselves, in which 
it is stated that patients need to be willing to actively 
participate in the DMP [16]. Consequently, it could be 
assumed that better educated and more active patients 
with fewer comorbidities were more likely to be enrolled 
in one of the DMPs. Previous studies have reported such 
selection effects. Although we could not observe such 
effects in our data, unobserved selection bias could have 
occurred resulting in overoptimistic effect estimates [22, 
28, 45]. Also, the strong association between guideline 
care and mortality might be partly attributable to selec-
tion processes. It is plausible that severely ill patients 
with low life expectancy or other severe illnesses such as 
cancer are treated less “aggressively” with medication for 
the secondary prevention of CHD. In contrast, we also 
have some indication for dilution of the observed posi-
tive effects: We do know that many of the patients ini-
tially not enrolled in a DMP were subsequently enrolled 
after the start of the study [27]. This treatment “crossing 
over”, for which we could not account in our models, as 
well as the potential spill-over effects that occurred with 
the implementation of DMPs are likely to have biased 
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the mortality effects in the direction of the null. Despite 
these limitations, non-randomized evaluations like this 
can be considered as the best available evidence, as rand-
omized designs are hardly possible within the given legal 
framework [20]. Another limitation of the study is its 
potentially limited power. Although we observed consid-
erable effect sizes for many of the analyzed associations, 
tests statistics were often not significant.
Conclusion
The German DMPs for DM and CHD are among the big-
gest programs worldwide, but evidence of effectiveness is 
weak. This study indicates mixed results, speaking weakly 
in favor of DMPs. However, treatment according to 
guideline care seems to be highly effective in this patient 
group. The development of the DMP-guideline care asso-
ciation over time indicates external effects, which should 
be subject of further investigations. More sophisticated 
and larger studies are needed to draw more reliable con-
clusions about the effectiveness of these programs for 
patients with diabetes and CHD.
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